King Pharmaceuticals Inc. has been granted approval by the U.S. Food and Drug Administration (FDA) to market Duodote (atropine and pralidoxime chloride injection) as a treatment for chemical nerve agent and insecticide poisoning. Duodote is a single, dual-chambered auto-injector containing two separate drug products, atropine and pralidoxime chloride. Duodote is intended for administration in the event of chemical nerve agent and insecticide poisoning. The auto-injector is a pre-filled, ready-to-use unit designed to treat symptoms caused by chemical nerve agents, and organophosphorous insecticides. Duodote replaces the Mark I Nerve Agent Auto-Injector Kit that contains two separate auto-injectors (two separate injections) - one containing atropine and one containing pralidoxime chloride.